Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 58 | 2023 | 2903 | 5.790 |
Why?
|
| Magnetic Resonance Imaging | 43 | 2023 | 3362 | 4.430 |
Why?
|
| Lymph Nodes | 8 | 2021 | 533 | 2.390 |
Why?
|
| Axilla | 11 | 2021 | 99 | 2.220 |
Why?
|
| Contrast Media | 34 | 2022 | 1078 | 2.210 |
Why?
|
| Lymphatic Metastasis | 11 | 2017 | 486 | 2.130 |
Why?
|
| Ultrasonography, Mammary | 7 | 2013 | 82 | 1.850 |
Why?
|
| Carcinoma, Ductal, Breast | 6 | 2021 | 157 | 1.630 |
Why?
|
| Image Interpretation, Computer-Assisted | 14 | 2018 | 663 | 1.520 |
Why?
|
| Breast | 13 | 2022 | 288 | 1.430 |
Why?
|
| Image Enhancement | 13 | 2021 | 563 | 1.400 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 13 | 2020 | 466 | 1.310 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2021 | 113 | 1.310 |
Why?
|
| Gadolinium DTPA | 13 | 2015 | 261 | 1.250 |
Why?
|
| Sensitivity and Specificity | 25 | 2022 | 1991 | 1.010 |
Why?
|
| ROC Curve | 19 | 2015 | 752 | 0.970 |
Why?
|
| Mammography | 9 | 2021 | 463 | 0.930 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 5 | 2022 | 294 | 0.910 |
Why?
|
| Radiologists | 1 | 2021 | 46 | 0.770 |
Why?
|
| Biopsy | 13 | 2022 | 1163 | 0.760 |
Why?
|
| Middle Aged | 48 | 2021 | 25028 | 0.750 |
Why?
|
| Radiography, Thoracic | 9 | 2006 | 320 | 0.740 |
Why?
|
| Female | 64 | 2023 | 44532 | 0.740 |
Why?
|
| Diagnosis, Differential | 20 | 2022 | 1565 | 0.730 |
Why?
|
| Aged | 37 | 2021 | 18415 | 0.700 |
Why?
|
| Diagnosis, Computer-Assisted | 7 | 2011 | 332 | 0.690 |
Why?
|
| Adult | 40 | 2022 | 25648 | 0.670 |
Why?
|
| Receptor, ErbB-2 | 4 | 2022 | 223 | 0.650 |
Why?
|
| Mass Screening | 6 | 2018 | 618 | 0.640 |
Why?
|
| Biopsy, Needle | 3 | 2010 | 235 | 0.640 |
Why?
|
| Humans | 81 | 2023 | 86643 | 0.620 |
Why?
|
| Retrospective Studies | 25 | 2023 | 8489 | 0.600 |
Why?
|
| Kinetics | 8 | 2022 | 1513 | 0.560 |
Why?
|
| Aged, 80 and over | 18 | 2020 | 6509 | 0.490 |
Why?
|
| Observer Variation | 14 | 2020 | 602 | 0.480 |
Why?
|
| User-Computer Interface | 3 | 2012 | 185 | 0.470 |
Why?
|
| Neoadjuvant Therapy | 6 | 2022 | 318 | 0.470 |
Why?
|
| Ultrasonography, Interventional | 2 | 2013 | 121 | 0.430 |
Why?
|
| Lung Diseases, Interstitial | 4 | 2005 | 235 | 0.410 |
Why?
|
| Diagnostic Imaging | 2 | 2013 | 469 | 0.410 |
Why?
|
| Organometallic Compounds | 3 | 2016 | 132 | 0.380 |
Why?
|
| Lung Neoplasms | 11 | 2008 | 2262 | 0.370 |
Why?
|
| Neoplasm Staging | 8 | 2018 | 1939 | 0.370 |
Why?
|
| Tomography, Spiral Computed | 3 | 2004 | 76 | 0.360 |
Why?
|
| Carcinoma | 1 | 2013 | 436 | 0.350 |
Why?
|
| Lung Diseases | 4 | 2004 | 263 | 0.330 |
Why?
|
| Solitary Pulmonary Nodule | 7 | 2006 | 138 | 0.320 |
Why?
|
| Decision Making | 1 | 2013 | 642 | 0.320 |
Why?
|
| Reproducibility of Results | 13 | 2018 | 2705 | 0.300 |
Why?
|
| Mastectomy, Segmental | 2 | 2021 | 93 | 0.300 |
Why?
|
| Ultrasonography | 3 | 2017 | 695 | 0.290 |
Why?
|
| Prospective Studies | 10 | 2022 | 4213 | 0.270 |
Why?
|
| Young Adult | 8 | 2021 | 5976 | 0.270 |
Why?
|
| Meglumine | 2 | 2016 | 39 | 0.260 |
Why?
|
| Pattern Recognition, Automated | 4 | 2011 | 217 | 0.260 |
Why?
|
| Calcinosis | 4 | 2011 | 224 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2021 | 468 | 0.250 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 298 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2017 | 1204 | 0.240 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 68 | 0.230 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2016 | 579 | 0.230 |
Why?
|
| Breast Density | 2 | 2020 | 31 | 0.220 |
Why?
|
| Preoperative Care | 2 | 2016 | 397 | 0.210 |
Why?
|
| Incidental Findings | 2 | 2013 | 95 | 0.200 |
Why?
|
| Algorithms | 8 | 2017 | 1830 | 0.200 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 266 | 0.190 |
Why?
|
| Reference Standards | 1 | 2021 | 159 | 0.180 |
Why?
|
| Prognosis | 3 | 2013 | 3679 | 0.180 |
Why?
|
| Fibroadenoma | 1 | 2019 | 9 | 0.180 |
Why?
|
| Radiographic Image Enhancement | 4 | 2009 | 462 | 0.180 |
Why?
|
| Microvessels | 1 | 2018 | 70 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1019 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2005 | 2601 | 0.150 |
Why?
|
| Computer Simulation | 3 | 2015 | 1078 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 200 | 0.150 |
Why?
|
| Subtraction Technique | 3 | 2006 | 133 | 0.150 |
Why?
|
| Clinical Competence | 3 | 2009 | 751 | 0.150 |
Why?
|
| Information Storage and Retrieval | 3 | 2013 | 120 | 0.150 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2018 | 103 | 0.140 |
Why?
|
| Early Detection of Cancer | 2 | 2018 | 394 | 0.140 |
Why?
|
| False Negative Reactions | 2 | 2013 | 63 | 0.140 |
Why?
|
| Fourier Analysis | 1 | 2016 | 125 | 0.140 |
Why?
|
| Adipose Tissue | 2 | 2008 | 240 | 0.130 |
Why?
|
| Metabolic Clearance Rate | 1 | 2015 | 121 | 0.130 |
Why?
|
| Area Under Curve | 5 | 2018 | 334 | 0.130 |
Why?
|
| Radiography | 3 | 2012 | 813 | 0.130 |
Why?
|
| Signal-To-Noise Ratio | 3 | 2019 | 96 | 0.120 |
Why?
|
| Support Vector Machine | 1 | 2013 | 25 | 0.120 |
Why?
|
| Genomics | 1 | 2019 | 720 | 0.120 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2013 | 36 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1384 | 0.120 |
Why?
|
| Radiology Information Systems | 1 | 2013 | 76 | 0.110 |
Why?
|
| Medical Records | 1 | 2013 | 119 | 0.110 |
Why?
|
| Models, Theoretical | 3 | 2018 | 482 | 0.110 |
Why?
|
| Phenotype | 2 | 2019 | 2378 | 0.110 |
Why?
|
| Breast Diseases | 2 | 2011 | 97 | 0.110 |
Why?
|
| Echo-Planar Imaging | 2 | 2017 | 52 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 1673 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 100 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2012 | 303 | 0.100 |
Why?
|
| Illinois | 1 | 2013 | 462 | 0.100 |
Why?
|
| Lymph Node Excision | 2 | 2013 | 217 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2015 | 395 | 0.100 |
Why?
|
| Prevalence | 2 | 2013 | 1239 | 0.090 |
Why?
|
| Models, Biological | 2 | 2015 | 1749 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2018 | 2261 | 0.090 |
Why?
|
| False Positive Reactions | 3 | 2005 | 216 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1313 | 0.090 |
Why?
|
| Computer Terminals | 1 | 2009 | 7 | 0.090 |
Why?
|
| Adolescent | 2 | 2019 | 8981 | 0.090 |
Why?
|
| Carcinoma, Ductal | 1 | 2008 | 18 | 0.080 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2008 | 38 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 81 | 0.080 |
Why?
|
| Feasibility Studies | 3 | 2017 | 751 | 0.080 |
Why?
|
| Artifacts | 2 | 2018 | 244 | 0.070 |
Why?
|
| Ribs | 1 | 2006 | 45 | 0.070 |
Why?
|
| Lung | 4 | 2005 | 1170 | 0.070 |
Why?
|
| Radiology | 2 | 2008 | 194 | 0.060 |
Why?
|
| Risk Factors | 2 | 2014 | 5417 | 0.060 |
Why?
|
| Intracranial Aneurysm | 1 | 2004 | 158 | 0.060 |
Why?
|
| Neoplasms | 1 | 2018 | 2898 | 0.060 |
Why?
|
| Gastric Mucosa | 1 | 2023 | 66 | 0.060 |
Why?
|
| Radiology, Interventional | 1 | 2004 | 68 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2004 | 1805 | 0.060 |
Why?
|
| Quality Control | 2 | 2018 | 117 | 0.060 |
Why?
|
| Life Style | 1 | 2023 | 189 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 37 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 141 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 262 | 0.050 |
Why?
|
| Machine Learning | 1 | 2023 | 232 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2015 | 839 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 1204 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 479 | 0.040 |
Why?
|
| Smoking | 1 | 2003 | 609 | 0.040 |
Why?
|
| Gadolinium | 1 | 2019 | 103 | 0.040 |
Why?
|
| Male | 7 | 2005 | 40965 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 2018 | 144 | 0.040 |
Why?
|
| Radiation Dosage | 3 | 2004 | 227 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2021 | 7993 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 220 | 0.040 |
Why?
|
| Time | 1 | 2016 | 77 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1621 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1961 | 0.030 |
Why?
|
| Entropy | 1 | 2015 | 38 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2767 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 307 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 93 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1169 | 0.030 |
Why?
|
| Diagnostic Errors | 2 | 2005 | 160 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 167 | 0.030 |
Why?
|
| Software | 1 | 2017 | 654 | 0.030 |
Why?
|
| Apoptosis | 1 | 2019 | 1683 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 2438 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1718 | 0.030 |
Why?
|
| Adenocarcinoma | 3 | 2004 | 1169 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 384 | 0.030 |
Why?
|
| Fats | 1 | 2011 | 12 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 552 | 0.030 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 137 | 0.030 |
Why?
|
| Injections | 1 | 2010 | 109 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 912 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 396 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2271 | 0.020 |
Why?
|
| Liquid Crystals | 1 | 2009 | 12 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 229 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 3968 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2006 | 369 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2004 | 148 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 134 | 0.010 |
Why?
|
| Japan | 1 | 2003 | 307 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 5210 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 1577 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 3640 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 1076 | 0.010 |
Why?
|